



A Better Way to Monitor Inflammatory Bowel Disease

Why EUPHORIA?

Inflammatory Bowel Disease (IBD) is a chronic condition affecting more than 2.5 million people in Europe. People with IBD undergo flares of intestinal inflammation which may lead to surgical treatments, unemployment, sick leave and work disability. Adequate medical treatment including accurate diagnostics can reduce symptoms and prevent complications. However, endoscopic monitoring for the management of IBD is an invasive and ill-tolerated procedure.

Multispectral Optoacoustic Tomography (MSOT) has the unique ability to non-invasively measure perfusion and oxygenation as biomarkers of intestinal inflammation.

EUPHORIA is a Horizon 2020-funded project delivered by a consortium of leading European partners. The project aim is to optimize iThera Medical's handheld optoacoustic imaging platform for the assessment of inflammation in people with IBD and make it available to doctors and hospitals for routine use.

What we do?

EUPHORIA is enabling iThera Medical and its partners to enter a new phase, moving from clinical research into routine care.

EUPHORIA will:

- Customize MSOT hardware to get the best possible results in IBD
- Create better images of difficult-to-see tissues, using new software
- Verify that MSOT is an attractive alternative to endoscopy in a substantial clinical trial
- Get ready for the market by obtaining a CE mark
- Conduct a rigorous health economic assessment to convince hospitals and healthcare payors that MSOT is an effective, reimbursable, validated clinical procedure
- Work with insurance companies and health agencies towards reimbursement approval.

Why we do it?

EUPHORIA will enable wider access to MSOT technology to IBD patients. MSOT uses light and sound to create images. It is non-invasive, patient-friendly and less costly than MRI or CT. It has particular value in IBD, because of its ability to differentiate between many types of soft tissue and fluid, within the body - this enables more accurate diagnosis and more sensitive monitoring of IBD than other technologies. Successful execution of the clinical study will confirm its benefits to patients, doctors, hospitals, and ultimately also to payors, healthcare systems and society.

EUPHORIA is an EU-supported project which takes novel technology breakthroughs to the market – and the clinic.

Find out more: www.euphoria2020.eu

Our European Consortium



iThera Medical is the leading manufacturer worldwide of clinical optoacoustic devices.

Dr Philipp Bell
Jin He

Dr Patricia Smole
Christian Wiest
Dr Amy Lin

Dr Nina Dahlhaus
Dr Manuela Bung



University Hospital Erlangen, one of the largest IBD centers in Germany is ideally suited for clinical validation.

Prof. Dr Markus Neurath

Prof. Dr Maximilian Walner

Dr Ferdinand Knieling



IMASONIC is a world leader in the development and manufacture of ultrasonic transducers.

Dr Mikael Wilm
Dr Etienne Coffy

Bruno Klinguer
Dr Frédéric Brochin

Olivier Le Baron
Gerard Fleury



RAYFOS delivers specialized software for fast data acquisition and real time image processing.

Vassilis Sarantos



Pintail Limited is an expert management and communications SME.

Ciaran Clissmann

Dr Kylie O'Brien

Danielle Nicholson

Media

Dr Manuela Bung
iThera Medical GmbH
Zielstattstraße 13, 81379 München, Germany
manuela.bung@ithera-medical.com

Follow us:



@euphoriah2020



@EUPHORIAH2020



This project has received funding from the European Union's Horizon 2020 research and innovation fund under grant agreement no 830965. The materials presented and views expressed here are the responsibility of the authors only. The EU Commission takes no responsibility for any use made of the information set out.

© EUPHORIA, 2019